CD274 and endometrium adenocarcinoma: Therefore, new drug modalities targeting ezrin may be effective for reducing the PD-L1 expression on the cell surface of human endometrial adenocarcinoma and providing a novel therapeutic option to enhance the response rate of ICB therapies.